This site is intended for health professionals only
Sunday 25 September 2016 Instagram
Share |

NICE recommends new treatment for osteoporotic fractures

NICE recommends new treatment for osteoporotic fractures

NICE today recommends denosumab (Prolia) as a treatment option forcertain postmenopausal women who are at increased risk of primary andsecondary osteoporotic fractures if other treatments available on the NHS are unsuitable.

NICE currently recommends a range of treatment options for reducing the risk of postmenopausal women suffering either a first osteoporotic fracture or a further fracture. Most women are prescribed alendronate in the first instance before being prescribed risedronate or etidronate, but for some, these drugs (classed as oral bisphosphonates) may be unsuitable.

For example, some postmenopausal women may not be able to comply with the special instructions for administration of oral bisphosphonates, or they may have a contraindication to, or intolerance of, oral bisphosphonates. For certain women at increased risk of fractures who can’t take alendronate, nor either risedronate or etidronate, denosumab is now one of the possible treatment options.

Dr Carole Longson, Health Technology Evaluation Centre Director at NICE said: “We are pleased to be able to recommend denosumab to help prevent osteoporotic fractures in postmenopausal women at increased risk of fracture who are unable to take oral bisphosphonates.

"Denosumab joins the range of treatments that NICE has already advised should be available on the NHS, to help stop a fracture from occurring in the first place, or to help women who have previously had a fracture. This new guidance is good news for postmenopausal women at increased risk of fracture as it means that they now have a further treatment option to help them avoid suffering an osteoporotic fracture.”

NICE

Ads by Google

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?